Drug Trial Radar · NCT05488340
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
Last checked: Nov 20, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
318
Planned (sponsor's estimate)
Start
Jul 13, 2022
Primary completion
Jun 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Locus BiosciencesIndustry
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Aug 4, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the subsequent 288 patient blinded portion of the study which will be randomized 1:1 comparing LBP-EC01 + antibiotic versus placebo + antibiotic in patients with a history of prior urinary tract infection (UTI) cased by E. coli. All patients will be required to have an active acute uncomplicated UTI at baseline.
Conditions
- Urinary Tract Infections
Interventions
LBP-EC01 0.1 x IV doseDrug
Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.6mL of LBP-EC01 (approximately 1x10\^11 PFU) diluted in 0.4mL of Lactated Ringer's solution given on Days 1 through Day 3.
LBP-EC01 0.01x IV DoseDrug
Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous (IV) dose of 0.06 mL of LBP-EC01 (approximately 1x10\^10 PFU) diluted in 0.94 mL of Lactated Ringer's solution given on Days 1 through Day 3.
LBP-EC01 IV Infusion DoseDrug
Intraurethral (IU) dose of two (2) x 6mL vials of LBP-EC01 (approximately 2x10\^12 PFU) diluted in 188 mL of Lactated Ringer's solution on Day 1 and Day 2. Intravenous infusion dose of 6mL of LBP-EC01 (approximately 1x10\^12 PFU) diluted in 94 mL of Lactated Ringer's solution given over 2 hours on Days 1 through Day 3.
PlaceboDrug
Dose regimen selected from Part 1 of placebo (Tris buffer).
LBP-EC01Drug
Dose regimen selected from Part 1 of LBP-EC01 (1x10\^10 - 1x10\^13 PFU) per dose.
TMP/SMXDrug
TMP/SMX (160 mg trimethoprim and 800 mg sulfamethoxazole) given orally BID on Days 1 through 3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Levels of LBP-EC01 in urine and blood measured by quantitative plaquing assay across the treatment period and over 48 h after the last doseTime frame: Day 1 to Day 5
- Part 2: Proportion of patients with resolution of clinical symptoms and microbiologic response of uUTI caused by drug resistant E. coli as defined at Day 10 test of cure (TOC).Time frame: Day 10
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Research Site 138
Fresno, California · Completed
Research Site 131
Lancaster, California · Recruiting
Research Site 123
Los Angeles, California · Recruiting
Research Site 125
Montebello, California · Completed
Research Site 152
Murrieta, California · Recruiting
Research Site 137
San Diego, California · Recruiting
Research Site 126
Tustin, California · Recruiting
Research Site 102
Doral, Florida · Recruiting
Research Site 151
Hialeah, Florida · Recruiting
Research Site 140
Jensen Beach, Florida · Completed
Research Site 103
Miami, Florida · Recruiting
Research Site 149
Miami, Florida · Recruiting
Research Site 153
Ocala, Florida · Recruiting
Research Site 120
Boston, Massachusetts · Completed
Research Site 154
St Louis, Missouri · Recruiting
Research Site 145
Raleigh, North Carolina · Recruiting
Research Site 118
Winston-Salem, North Carolina · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.